UroGen Pharma Announces Positive Clinical Trial Results for Bladder Cancer Treatment ZUSDURI

Key Facts

1ZUSDURI™ achieved durable complete responses in patients with recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC).

2Recurrence score analysis from the pivotal ENVISION trial will be presented at the ASCO-GU 2026 symposium.

3The results demonstrated efficacy across various EORTC risk groups.

UroGen Pharma Ltd. (URGN) has announced positive clinical data from its pivotal ENVISION trial for ZUSDURI™ (UGN-102). The drug achieved durable complete responses in patients suffering from recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC). According to the report, the results demonstrated significant efficacy across various risk groups as classified by the EORTC. The company plans to present a detailed recurrence score analysis at the upcoming ASCO-GU 2026 symposium. These findings support ZUSDURI’s potential as a primary treatment option, marking a significant regulatory milestone for the company. Investors view this development as a major catalyst for UroGen's oncology pipeline and future commercial prospects.